Friederika Aceto Ph D Clinical is categorized under Nonclassified Establishments in Braintree, MA and active since 2006.
Friederika Aceto Ph D Clinical was established in 2006, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Nonclassified Establishments business, which does work in the BOTH market, and is classified as a Nonclassified Establishments, under code number 6213300 by the NAICS.
If you are seeking more information, feel free to contact Friederika Aceto at the company’s single location by writing to 8 Washington Place, Braintree, Massachusetts MA 02184 or by phoning (781) 519-4320. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
Business Name: | Friederika Aceto Ph D Clinical |
Contact Person: | Friederika Aceto |
Address: | 8 Washington Place, Braintree, Massachusetts 02184 |
Phone Number: | (781) 519-4320 |
Annual Revenue (USD): | $100.000 to $499.999 |
Founded: | 2006 |
Location Type: | Single Location |
Employee Number: | 1 to 4 |
Business Type: | B2B & B2C |
Business Category: | Nonclassified Establishments |
SIC Code: | 9999 |
NAICS Code: | 6213300 |
Share This Business: |
Friederika Aceto Ph D Clinical was started in 2006 to provide professional Nonclassified Establishments under the SIC code 9999 and NAICS code 6213300. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Friederika Aceto for inquiries that concern Friederika Aceto Ph D Clinical by calling the company number (781) 519-4320, as your correspondence is most welcome. Additionally, the physical location of the single location of Friederika Aceto Ph D Clinical can be found at the coordinates 42.22041,-71.00319 as well as the street address 8 Washington Place in Braintree, Massachusetts 02184.
For its online presence, you may visit Friederika Aceto Ph D Clinical’s website at and engage with its social media outlets through on Twitter and on Facebook.